NimBio wins EIT Health IBD Challenge with innovative inflammation monitoring solution

The challenge called on European start-ups to develop a solution for fast, regular, and minimally invasive remote monitoring of people with Inflammatory Bowel Disease (IBD), a condition affecting millions worldwide. The goal: enable earlier detection of flares and more personalised, proactive care.

Out of ten start-ups shortlisted across Europe, NimBio’s Inflammometer stood out as the most promising solution. Powered by predictive AI and passive bio-sensing, the technology continuously tracks inflammation levels through everyday wearables, detecting early warning signs before symptoms appear.

The EIT Health Open Innovation programme supports start-ups like NimBio in refining their value proposition and scaling their impact through close collaboration with healthcare and industry partners.

“Winning this challenge is a major step forward in our mission to make inflammation measurable, actionable, and preventable,” says Tal Atarot, Co-founder of NimBio. “Together with Takeda and KU Leuven, we’re turning innovation into real-world impact for IBD patients.”